Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1981 2
1983 2
1984 4
1985 3
1986 3
1987 12
1988 5
1989 6
1991 8
1992 2
1993 4
1994 4
1995 6
1996 4
1997 7
1998 6
1999 1
2000 6
2001 5
2002 6
2003 4
2004 3
2005 1
2006 2
2007 2
2008 4
2009 4
2010 3
2011 2
2012 6
2013 5
2015 4
2016 1
2017 1
2018 4
2019 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

139 results

Results by year

Filters applied: . Clear all
Page 1
Oral misoprostol and vaginal isosorbide mononitrate for labor induction: a randomized controlled trial.
Collingham JP, Fuh KC, Caughey AB, Pullen KM, Lyell DJ, El-Sayed YY. Collingham JP, et al. Obstet Gynecol. 2010 Jul;116(1):121-126. doi: 10.1097/AOG.0b013e3181e408f2. Obstet Gynecol. 2010. PMID: 20567177 Clinical Trial.
OBJECTIVE: To estimate whether vaginal isosorbide mononitrate, added to oral misoprostol for cervical ripening and labor induction, shortens time to vaginal delivery. ...Side effects were also similar between groups, except that women given isosorbide …
OBJECTIVE: To estimate whether vaginal isosorbide mononitrate, added to oral misoprostol for cervical ripening and labor induc …
Isosorbide-5-mononitrate and isosorbide dinitrate retard in the treatment of coronary heart disease: a multi-centre study.
Bidoggia H. Bidoggia H. Curr Med Res Opin. 1987;10(9):601-11. doi: 10.1185/03007998709112414. Curr Med Res Opin. 1987. PMID: 3325229 Clinical Trial.
Analysis of the results showed that the more frequently angina attacks had occurred during the basal period, the greater was therapeutic benefit obtained with isosorbide-5-mononitrate compared to isosorbide dinitrate retard at the end of the study. ...Diastol …
Analysis of the results showed that the more frequently angina attacks had occurred during the basal period, the greater was therapeutic ben …
Isosorbide-5-mononitrate and atenolol in the treatment of stable exertional angina.
Waysbort J, Meshulam N, Brunner D. Waysbort J, et al. Cardiology. 1991;79 Suppl 2:19-26. doi: 10.1159/000174920. Cardiology. 1991. PMID: 1760824 Clinical Trial.
Fourteen men and six women, 48-68 years old, with stable angina and effort-induced ST-segment depression (ST-D) were treated with isosorbide-5-mononitrate (IS-5-MN) 2 x 40 mg/day and/or atenolol (AT) 100 mg/day in a double-blind randomized sequence during two …
Fourteen men and six women, 48-68 years old, with stable angina and effort-induced ST-segment depression (ST-D) were treated with isosorb …
Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction.
Redfield MM, Anstrom KJ, Levine JA, Koepp GA, Borlaug BA, Chen HH, LeWinter MM, Joseph SM, Shah SJ, Semigran MJ, Felker GM, Cole RT, Reeves GR, Tedford RJ, Tang WH, McNulty SE, Velazquez EJ, Shah MR, Braunwald E; NHLBI Heart Failure Clinical Research Network. Redfield MM, et al. N Engl J Med. 2015 Dec 10;373(24):2314-24. doi: 10.1056/NEJMoa1510774. Epub 2015 Nov 8. N Engl J Med. 2015. PMID: 26549714 Free PMC article. Clinical Trial.
BACKGROUND: Nitrates are commonly prescribed to enhance activity tolerance in patients with heart failure and a preserved ejection fraction. We compared the effect of isosorbide mononitrate or placebo on daily activity in such patients. ...During all dose regimens, …
BACKGROUND: Nitrates are commonly prescribed to enhance activity tolerance in patients with heart failure and a preserved ejection fraction. …
Poor tolerance and limited effects of isosorbide-5-mononitrate in microvascular angina.
Wu M, Villano A, Russo G, Di Franco A, Stazi A, Lauria C, Sestito A, Lanza GA, Crea F. Wu M, et al. Cardiology. 2015;130(4):201-6. doi: 10.1159/000370027. Epub 2015 Mar 12. Cardiology. 2015. PMID: 25790943 Clinical Trial.
OBJECTIVES: To assess the effects of isosorbide-5-mononitrate (ISMN) in patients with microvascular angina (MVA). ...CONCLUSIONS: In this study, a high proportion of MVA patients showed an intolerance to ISMN; in those tolerating the drug, significant …
OBJECTIVES: To assess the effects of isosorbide-5-mononitrate (ISMN) in patients with microvascular angina (MVA) …
Vericiguat in combination with isosorbide mononitrate in patients with chronic coronary syndromes: The randomized, phase Ib, VISOR study.
Boettcher M, Mikus G, Trenk D, Düngen HD, Donath F, Werner N, Karakas M, Besche N, Schulz-Burck D, Gerrits M, Hung J, Becker C. Boettcher M, et al. Clin Transl Sci. 2022 May;15(5):1204-1214. doi: 10.1111/cts.13238. Epub 2022 Mar 17. Clin Transl Sci. 2022. PMID: 35299288 Free PMC article. Clinical Trial.
This study evaluated safety, tolerability, and the pharmacodynamic (PD) interaction between co-administered vericiguat and isosorbide mononitrate in patients with CCS. In this phase Ib, double-blind, multicenter study, patients were randomized 2:1 to receive vericig …
This study evaluated safety, tolerability, and the pharmacodynamic (PD) interaction between co-administered vericiguat and isosorbide …
Chronic therapy with isosorbide-5-mononitrate causes endothelial dysfunction, oxidative stress, and a marked increase in vascular endothelin-1 expression.
Oelze M, Knorr M, Kröller-Schön S, Kossmann S, Gottschlich A, Rümmler R, Schuff A, Daub S, Doppler C, Kleinert H, Gori T, Daiber A, Münzel T. Oelze M, et al. Eur Heart J. 2013 Nov;34(41):3206-16. doi: 10.1093/eurheartj/ehs100. Epub 2012 May 3. Eur Heart J. 2013. PMID: 22555214
AIMS: Isosorbide-5-mononitrate (ISMN) is one of the most frequently used compounds in the treatment of coronary artery disease predominantly in the USA. ...The adverse effects of ISMN were improved in gp91phox knockout mice and normalized by bos …
AIMS: Isosorbide-5-mononitrate (ISMN) is one of the most frequently used compounds in the treatment of coronary artery …
Isosorbide mononitrate increases bone formation and decreases bone resorption in postmenopausal women: a randomized trial.
Jamal SA, Cummings SR, Hawker GA. Jamal SA, et al. J Bone Miner Res. 2004 Sep;19(9):1512-7. doi: 10.1359/JBMR.040716. Epub 2004 Jul 26. J Bone Miner Res. 2004. PMID: 15312252 Free article. Clinical Trial.
MATERIALS AND METHODS: We randomly assigned 144 healthy postmenopausal women with a hip BMD T score between 0 and -2.5 to 5 or 20 mg/day of isosorbide mononitrate (ISMO) or placebo for 12 weeks. We measured urine N-telopeptide (NTx), a marker of bone resorption, and …
MATERIALS AND METHODS: We randomly assigned 144 healthy postmenopausal women with a hip BMD T score between 0 and -2.5 to 5 or 20 mg/day of …
Addition of propranolol and isosorbide mononitrate to endoscopic variceal ligation does not reduce variceal rebleeding incidence.
Kumar A, Jha SK, Sharma P, Dubey S, Tyagi P, Sharma BC, Sarin SK. Kumar A, et al. Gastroenterology. 2009 Sep;137(3):892-901, 901.e1. doi: 10.1053/j.gastro.2009.05.049. Epub 2009 May 27. Gastroenterology. 2009. PMID: 19481079 Clinical Trial.
Primary end points were rebleeding or death; secondary end points were new complications of portal hypertension or serious adverse effects. RESULTS: The actuarial probabilities of rebleeding 2 years after therapy were 27% in the combination group and 31% in the EVL …
Primary end points were rebleeding or death; secondary end points were new complications of portal hypertension or serious adverse …
139 results